Daily Media Digest September 25, 2018
Alnylam Pharmaceuticals Receives Priority Review in Canada for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy Canada NewsWire (press release) “… at the University of Toronto, Director […]